文献速递中毒与环境急症消化、代谢与肾脏急症

美国缉毒局将氢可酮复方产品重新列管后加州毒物控制系统报告的暴露趋势

Trends in hydrocodone combination product exposures reported to California Poison Control System (CPCS) following DEA rescheduling.
PubMed 文献 · Clin Toxicol (Phila) · 2020-08-25
一句话结论美国缉毒局将氢可酮复方产品从附表III调整至附表II后,加州毒物控制系统报告的氢可酮复方产品、曲马多和吗啡暴露显著减少,但海洛因和芬太尼暴露显著增加。

该研究收集加州毒物控制系统2012至2019年每月暴露数据,采用间断时间序列分析评估氢可酮复方产品重新列管前后氢可酮复方产品、曲马多、羟考酮、吗啡、可待因、芬太尼和海洛因暴露的变化,并分析严重结局(中度或重度健康影响)占比的变化。结果显示,重新列管后氢可酮复方产品、曲马多和吗啡月度暴露显著下降(p<0.001),海洛因和芬太尼暴露显著上升(p<0.001),氢可酮复方产品暴露导致严重结局的占比无显著变化。作者认为重新列管可能与处方阿片类暴露减少相关,但芬太尼和海洛因暴露增加。

要点

  • 美国缉毒局2014年10月6日将氢可酮复方产品从附表III调整至附表II后,加州毒物控制系统报告的氢可酮复方产品月度暴露显著下降(p<0.001)。
  • 同期曲马多和吗啡月度暴露也显著下降(p<0.001),但海洛因和芬太尼月度暴露显著增加(p<0.001)。
  • 重新列管后氢可酮复方产品暴露导致严重结局(中度或重度健康影响)的占比无显著变化。
  • 作者认为重新列管可能是减少药物暴露的有用监管策略,但其他举措也可能 contributing。

适用人群与场景

  • 加州毒物控制系统2012至2019年报告的阿片类药物暴露案例,包括氢可酮复方产品、曲马多、羟考酮、吗啡、可待因、芬太尼和海洛因暴露。

研究设计与关键结果

  • 研究类型为间断时间序列分析,数据来源为加州毒物控制系统2012至2019年月度暴露报告。
  • 重新列管后氢可酮复方产品、曲马多和吗啡月度暴露显著下降(p<0.001)。
  • 重新列管后海洛因和芬太尼月度暴露显著增加(p<0.001)。
  • 氢可酮复方产品暴露导致严重结局(中度或重度健康影响)的占比在重新列管前后无显著变化。

证据类型、等级与局限

  • 证据类型为基于毒物控制系统数据的间断时间序列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为重新列管可能是减少药物暴露的有用监管策略。
  • 作者指出其他举措也可能对暴露减少有贡献。
  • 作者认为重新列管高风险药物可能是改善公共健康的有效策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: On October 6, 2014, the United States Drug Enforcement Administration (DEA) implemented a regulatory change for hydrocodone combination products (HCPs), moving them from Schedule III to II, in an effort to decrease drug overdoses. Existing research suggests this regulatory action reduced HCP prescribing and dispensing; however, there is limited research assessing its possible effects on overdoses and accidental exposures.

OBJECTIVE: To analyze the changes in opioid exposures reported to the California Poison Control System (CPCS) before and after DEA rescheduling of HCPs.

METHODS: We collected monthly exposure data reported to CPCS from 2012 to 2019 and conducted interrupted time series analyses to assess changes in exposures after rescheduling for HCPs, tramadol, oxycodone, morphine, codeine, fentanyl, and heroin. Additional analyses were done to assess any changes in exposures resulting in severe outcomes (moderate or major health effects). For HCPs, we also conducted logistic regressions to identify characteristics of exposures resulting in severe outcomes before and after rescheduling.

RESULTS: Overall monthly opioid exposures reported to CPCS decreased after DEA rescheduling of HCPs. These decreases were significant for HCP, tramadol, and morphine (p < 0.001). Exposures significantly increased for heroin and fentanyl (p < 0.001). There were no significant changes in the share of severe outcomes attributed to HCP exposures after rescheduling.

DISCUSSION: The DEA rescheduling of HCPs was associated with a significant decrease in HCP exposures and prescription opioid exposures overall, but was associated with increased fentanyl and heroin exposures. While other initiatives may have contributed to this decrease, our findings suggest that rescheduling may be a useful regulatory strategy to reduce drug exposures.

CONCLUSION: DEA rescheduling of HCPs was associated with a significant reduction in prescription opioid exposures, suggesting that rescheduling high-risk drugs may be an effective strategy to improve public health.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Wu A, Phan C, Nguyen KC, et al. Trends in hydrocodone combination product exposures reported to California Poison Control System (CPCS) following DEA rescheduling. Clin Toxicol (Phila). 2020. PMID: 32840386. doi:10.1080/15563650.2020.1803350

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。